Literature DB >> 19924994

Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials.

Nicola Antonio Colabufo1, Francesco Berardi, Mariangela Cantore, Marialessandra Contino, Carmela Inglese, Mauro Niso, Roberto Perrone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19924994     DOI： 10.1021/jm900743c

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  25 in total

Review 1.  Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies.

Authors:  Ranjeet Prasad Dash; R Jayachandra Babu; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

Review 2.  Non-small cell lung cancer: the era of targeted therapy.

Authors:  Mara B Antonoff; Jonathan D'Cunha
Journal:  Lung Cancer (Auckl)       Date:  2012-07-02

3.  Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance.

Authors:  Konstantin Chegaev; Aurore Fraix; Elena Gazzano; Gamal Eldein F Abd-Ellatef; Marco Blangetti; Barbara Rolando; Sabrina Conoci; Chiara Riganti; Roberta Fruttero; Alberto Gasco; Salvatore Sortino
Journal:  ACS Med Chem Lett       Date:  2017-01-30       Impact factor: 4.345

4.  (99m)Tc(N)-DBODC(5), a potential radiolabeled probe for SPECT of multidrug resistance: in vitro study.

Authors:  Cristina Bolzati; Davide Carta; Valentina Gandin; Cristina Marzano; Nicolò Morellato; Nicola Salvarese; Mariangela Cantore; Nicola Antonio Colabufo
Journal:  J Biol Inorg Chem       Date:  2013-03-31       Impact factor: 3.358

5.  Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity.

Authors:  Konstantin Chegaev; Chiara Riganti; Loretta Lazzarato; Barbara Rolando; Stefano Guglielmo; Ivana Campia; Roberta Fruttero; Amalia Bosia; Alberto Gasco
Journal:  ACS Med Chem Lett       Date:  2011-04-04       Impact factor: 4.345

Review 6.  Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.

Authors:  Fionn E O'Brien; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

7.  P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells.

Authors:  Gemma Navarro; Rupa R Sawant; Swati Biswas; Sean Essex; Conchita Tros de Ilarduya; Vladimir P Torchilin
Journal:  Nanomedicine (Lond)       Date:  2012-01       Impact factor: 5.307

8.  Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.

Authors:  F E O'Brien; G Clarke; P Fitzgerald; T G Dinan; B T Griffin; J F Cryan
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 9.  Anti-tumor activities of matrine and oxymatrine: literature review.

Authors:  Yan Liu; Yang Xu; Weidan Ji; Xiaoya Li; Bin Sun; Quangen Gao; Changqing Su
Journal:  Tumour Biol       Date:  2014-02-14

10.  New tetrahydroisoquinoline-based P-glycoprotein modulators: decoration of the biphenyl core gives selective ligands.

Authors:  Marialessandra Contino; Stefano Guglielmo; Maria Grazia Perrone; Roberta Giampietro; Barbara Rolando; Antonio Carrieri; Daniele Zaccaria; Konstantin Chegaev; Vanessa Borio; Chiara Riganti; Katarzyna Zabielska-Koczywąs; Nicola A Colabufo; Roberta Fruttero
Journal:  Medchemcomm       Date:  2018-04-03       Impact factor: 3.597
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.